Stem Cell Therapeutics Corp. (SCT) is pleased to announce that Dr. Allen Davidoff, V.P. Product Development, will present a poster today at the "Back to the Science of Stem Cell Research" conference being held in Boston, MA, USA. The poster describes the positive results from a controlled study testing NTx(TM)-265 therapy in a rodent model of stroke. The study was co-authored by Dr. Steven Cramer of the University of California, Irvine, who is also the principle investigator of SCT's currently enrolling Phase IIa clinical trial investigating the safety of NTx(TM)-265 in human stroke patients.

The data presented confirms that, in test animals, treatment with the NTx(TM)-265 regimen of drugs produces substantial and significant recovery of lost neurological function. NTx(TM)-265 is a peripherally administered proprietary dose and schedule of human chorionic gonadotropin (hCG) followed by erythropoietin (EPO). hCG and EPO have both been marketed worldwide for years in other medical applications and extensive safety data exists for both molecules.

Stroke is the third leading cause of death in the United States, where it affects 700,000 people each year, and is the second leading killer worldwide. Stroke is also the leading cause of long-term disability. The American Heart Association estimates that death and injury due to stroke cost the US economy $56.8 billion in 2005.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a biotechnology company focused on the development of its technology platform and intellectual property to selectively induce a patient's own stem cells to proliferate in the brain. SCT's core technology, which includes its lead therapeutic product NTx(TM)-265, has been demonstrated to increase the number of innate adult stem cells that grow in place when this therapeutic approach is applied to test animals. SCT plans to develop this fundamental technology further for specific disease treatments such as stroke and potentially Huntington's disease, Alzheimer's disease and other neurodegenerative conditions.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Stem Cell Therapeutics Corp

Tag Cloud